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Abstract
Background: Current available treatments (benznidazole and nifurtimox) for Chagas disease (CD) show limited
efficacy in chronic phase and frequent undesirable effects. Ergosterol synthesis inhibitors (ESI) had been considered
as promising drugs for CD treatment and despite its recent poor results in several clinical trials, different strategies
have been proposed to optimize its role in this infection.
Case presentation: We present a case of chronic Chagas disease in patient diagnosed with HIV who received
treatment for histoplasmosis with itraconazol during twelve months. Even though T. cruzi rt-PCR was persistently
negative during treatment, when itraconazol was stopped she presented with a positive blood rt-PCR.
Conclusion: Several studies using different ESI had been published for CD treatment. Either in vitro or in vivo
assays demonstrated activity against T. cruzi of the different triazole derivatives so different clinical trials had been
carried out to evaluate its efficacy and safety. Despite contradictory evidence in the animal model, longer
treatments along with other treatment strategies previously proposed suggests that ESI failure rates in positive
peripheral blood rt-PCR are higher than that obtained with the current treatments of choice.
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Background
Despite of the growing consensus of treating Chagas dis-
ease (CD) in chronic stages to avoid the progression of
chagasic cardiomyopathy, current available treatments
(benznidazole and nifurtimox) show limited efficacy
reaching cure rates between 15 and 35% [1] and frequent
undesirable effects, which leads to definitive withdrawal of
the treatment in 13–32% of patients [2]. Triazole deriva-
tives (ketoconazole, itraconazole, posaconazole, voricona-
zole, ravuconazole) have been used for years as antifungal
treatments with a good pharmacokinetic and safety pro-
file. They act as selective inhibitors of T. cruzi ergosterol
synthesis showing potent intrinsic activity against the
parasite in both in-vitro and in-vivo models, and had been
considered as promising drugs for CD treatment [3].
Different strategies have been proposed to optimize its
outcomes in CD. Here we present a treatment failure,
after the longest treatment with ergosterol synthesis inhib-
itors (ESI) reported in a patient with chronic CD.
Case presentation
A 38-Year-Old woman presented with a 2 months history
of abdominal pain, weight loss and constipation. She was
born in Bolivia (Sucre), and moved to Barcelona 7 years
ago. She had no relevant pathological history. A Com-
puted tomography (CT) showed an ileal stenosis causing
intestinal occlusion. Considering a differential diagnosis
including malignancies, inflammatory disease or infectious
diseases an ileum resection with termino-terminal anasto-
mosis was carried out. The biopsy revealed the presence
of a granulomatous ileitis with a PAS and Gomori stain
showing fungal microorganisms and a real-time quantita-
tive polymerase-chain-reaction (qPCR) with a positive re-
sult for Histoplasma spp. An HIV serology was done
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showing an advanced HIV infection with a CD4 count of
63 cell/L (7%) and a viral load of 120,000 copies/mL. Due
to the fact that was the first contact to health system a
screening for imported diseases was offered including
hepatitis B and C, Treponema pallidum, Strongyloides
stercoralis and Trypanosoma cruzi serology and investiga-
tion for parasites in feces. Two positive serologic tests
were obtained for T. cruzi: one of them using recombinant
antigen (Bioelisa Chagas, Biokit, Lliçà d’ Amunt, Spain)
and the other one using a crude antigen (T. cruzi ELISA,
Ortho-Clinical Diagnostics, Johnson & Johnson, High
Wycombe, United Kingdom). Cardiac and gastrointestinal
involvement was assessed by a 12-lead electrocardiog-
raphy, chest radiography, an echocardiography, a barium
enema examination, and an esophagogram showing no
visceral involvement. We started antiretroviral therapy
with Tenofovir/Emtricitabine and Raltegravir with rapid
improve of CD4 count to normal values within 6months.
Histoplasmosis was treated with liposomal amphotericin
3mg/kg during 10 days followed by itraconazole 200mg/
12 h during 12months with monthly visits at the out-
patient clinic assessing adherence to treatment and ad-
verse effects. After 6months of ESI treatment a routine
qPCR [4] for T. cruzi in peripheral blood was repeated
with a negative result, but after 1 year of follow-up and
once treatment was stopped, a positive qPCR for T. cruzi
was obtain. Thus, she received first line treatment for CD
with benznidazole 5mg/Kg/day for 60 days with good tol-
erability, with yearly T. cruzi qPCR in peripheral blood
negative during 3 years of follow-up (Fig. 1).
Discussion and conclusions
Several studies have been published using different ESI for
CD treatment, initially against benznidazole resistant T.
cruzi strains. Ketoconazole demonstrated in vitro activity
against T. cruzi but failed to induce cure in patients with
chronic phase of the disease [5]. Other ergosterol
inhibitors were then tested and Venegas et al. demon-
strated the effectivity of itraconazole on 20 patients with
the negativization of the peripheral parasitemia in 50% of
the patients using xenodiagnoses on previously positive
patients and the decrease of sera lytic activity on the re-
sponder patients [6]. Urbina et al. found better cure rates
with posaconazole in acute and chronic murine models
compared to ketoconazole [4]. In the same line, Molina
et al. tested posaconazole in a murine model of acute and
chronic infection with cure rates of 90 and 60% respect-
ively, superior than those treated with benznidazole even
in immunosuppressed mice [7]. In humans, case reports
of successful treatment with the triazole derivative posaco-
nazole, have been published, even after benznidazole treat-
ment failure in immunosuppressed patients [8]. Hence,
different clinical trials had been carried out to evaluate the
efficacy and safety of different triazole derivatives. In the
CHAGASAZOL trial, posaconazole at different doses was
compared to benznidazole in peripheral blood positive
qPCR patients. Even when patients received the maximum
dose approved for human use, in the intention-to-treat
analysis, posaconazole showed higher treatment failure
rates measured by peripheral blood qPCR of as much as
80.7% compared to a 38.4% obtained with benznidazole
[9]. To come up with an optimization of treatments, after
some promising combination studies performed in mice
[10], the STOP-CHAGAS trial compared benznidazole
and posaconazole in monotherapy and in combination.
Benznidazole in monotherapy showed a parasitological
cure of 86.7%, higher than posaconazole in monotherapy
(13.3%) and even higher than both treatments in combin-
ation (80%) [3]. Later on, a ravuconazole prodrug, which
had a better biodisponibility and half-live, was also tested
in a clinical trial. In that study, treatment with different
doses of ravuconazole was compared to standard treat-
ment with benznidazole. After a 12-month follow-up, only
29% of patients treated with high-dose ravuconazol had
Fig. 1 Timeline of case presentation Description: Timeline describing patient evolution regarding HIV, Histoplasma and Chagas disease. Legends:
BZD: Benznidazole, CD: Chagas disease, CD4: CD4+ Leucocytes T count, HC: Histoplasmosis, HIV: Human immunodeficiency virus, L-AMB:
Liposamal Amphotericine B, qPCR: real-time quantitative polymerase-chain-reaction, Tc: Trypanosoma cruzi, VL: Viral load
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sustained parasite response compared to 82% in patients
treated with benznidazole [11]. Recently, different studies
testing ESI in mice using novel test of cure as the biolumin-
escence, showed poor results. Francisco et al. performed a
chronic phase murine model whereas benznidazole showed
a 100% of parasitological cure, posaconazole failed in al-
most all cases. These inferior cure rates were also observed
when tested in the acute model when new cure standard
were applied [12]. Different mechanisms were proposed to
explain these results. In the late chronic stage of CD, T.
cruzi may have quiescent amastigote forms with low repli-
cative rates, therefore treatment using ESI, which also acts
during the replicative phase, could not be enough to elimin-
ate the parasite [13]. Additionally, it has been stated that
the dose of posaconazole used in both clinical trials, al-
though being the maximum approved in humans, would
suppose a drug exposure of 10 to 20% of the cure dose ad-
ministered in mice [14]. Hence, longer treatments with ESI
have been suggested to overcome that lack of efficacy. The
patient presented here received twelve months of itracona-
zole to treat an ileal histoplasma infection. However, erratic
drug absorption and distribution could have occurred since
drug levels during treatment were not obtained. Although
little evidence is derived from a single case, our patient
showed a positive qPCR persistence in peripheral blood at
the end of treatment, which is in line with a previous case
published by Galhardo et al. [15] and previous murine
models suggesting scarce benefit of prolonged ESI treat-
ment [16]. In our opinion, despite the contradictory evi-
dence of ESI in the animal model, all published data
including our case suggests that ESI failure rates in positive
peripheral blood qPCR are higher than that obtained with
the current treatments of choice. Due to the fact that HIV
patients are at risk of reactivation, prompt etiological treat-
ment and close follow-up should be guaranteed.
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